Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norketamine SCHEMBL30089863 | 1.00 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL12601750 | 1.00 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL30089862 | 1.00 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL12601748 | 1.00 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL30714777 | 1.00 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL30546347 | 0.98 | GRIN1 (0.57) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL29626880 | 0.98 | GRIN1 (0.57) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL29626917 | 0.98 | GRIN1 (0.57) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21452531 | 0.98 | GRIN1 (0.57) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL1997948 | 0.98 | GRIN1 (0.57) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| CN-114716332-B | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2023-06-02 | — | — | CN | claimed |
| US-20230000797-A1 | COMPOSITIONS AND METHODS FOR TREATING MOTOR DISORDERS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-01-05 | — | — | US | claimed |
| US-20220401366-A1 | LONG ACTING NMDA ANTAGONISTS | CONSEGNA PHARMA INC (US) | 2022-12-22 | — | — | US | claimed |
| US-20220378777-A1 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDER OR A RELATED CONDITION THEREOF | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-12-01 | — | — | US | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| US-11426366-B2 | Compositions and methods for treating motor disorders | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSSITY OF ARIZONA (US) | 2022-08-30 | — | — | US | claimed |
| CN-114716332-A | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021108801-A2 | LONG ACTING NMDA ANTAGONISTS | CONSEGNA PHARMA, INC. (US) | 2021-06-03 | — | — | WO | claimed |
| WO-2021087258-A1 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDER OR A RELATED CONDITION THEREOF | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-05-06 | — | — | WO | claimed |
| CN-110818587-A | Preparation method of ketamine and synthesis method of intermediate compound | 宜昌人福药业有限责任公司 | 2020-02-21 | — | — | CN | claimed |
| CN-122070289-A | Hydroxynorketamine analogues and uses thereof | 灵飞制药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260130869-A1 | ORAL DOSAGE FORM OF KETAMINE | KETABON GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| US-12611386-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2026-04-28 | — | — | US | disclosed |
| US-20260109663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA PHARM INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-1333023-A1 | Haptens, immunogens, antibodies and conjugates to ketamine and its metabolites | Randox Laboratories Ltd. (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-5384331-A | Ketamine analogues for treatment of thrombocytopenia | GENENTECH, INC. (US) | 1995-01-24 | — | — | US | disclosed |
| EP-0623343-A1 | Ketamine analogues for the treatment of thrombocytopenia | GENENTECH, INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| US-5250732-A | Influence replication, differentiation or maturation of platelet progenitor cells | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000797-A1 | COMPOSITIONS AND METHODS FOR TREATING MOTOR DISORDERS | SNCA, PARK7, COMT | GRIN1 77/4885GRIN2A 38/4885SLC6A4 138/4885 |
| US-20260109663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | SLC6A4, KCNK4, KCNJ11 | GRIN1 82/4885GRIN2A 116/4885SLC6A4 1/4885 |
| US-20260130869-A1 | ORAL DOSAGE FORM OF KETAMINE | KCNQ2, KCNQ1, KCNQ3 | GRIN1 122/4885GRIN2A 125/4885SLC6A4 315/4885 |
| US-12611386-B2 | Extended release pharmaceutical formulation | HTR1D, GRIN1, GRIN2D | GRIN1 2/4885GRIN2A 7/4885SLC6A4 16/4885 |
| US-11426366-B2 | Compositions and methods for treating motor disorders | COMT, SNCA, PARK7 | GRIN1 86/4885GRIN2A 40/4885SLC6A4 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.